Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

13.80USD
4:00pm EDT
Change (% chg)

$-0.08 (-0.58%)
Prev Close
$13.88
Open
$13.75
Day's High
$13.94
Day's Low
$13.59
Volume
68,721
Avg. Vol
126,883
52-wk High
$48.74
52-wk Low
$12.52

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 3.26
Market Cap(Mil.): $493.84
Shares Outstanding(Mil.): 35.58
Dividend: --
Yield (%): --

Financials

  FPRX.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -4.20 -- --
ROI: -35.70 1.50 12.72
ROE: -38.46 0.19 14.85

BRIEF-Five Prime Therapeutics Announces Collaboration With Roche

* FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES

May 30 2018

BRIEF-Five Prime Therapeutics Appoints Bryan Irving As Chief Scientific Officer

* FIVE PRIME THERAPEUTICS APPOINTS BRYAN IRVING, PH.D., AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

Apr 17 2018

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

Apr 10 2018

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

Apr 03 2018

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Mar 28 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥4,830 +140.00
Novartis AG (NOVN.S) CHF81.80 -0.08
AstraZeneca plc (AZN.L) 5,652.00 -18.00
Eli Lilly And Co (LLY.N) $105.59 -0.74
ArQule, Inc. (ARQL.OQ) $5.33 +0.25

Earnings vs. Estimates